The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics

Biomaterials

Volumn 66, Issue , 2015, Pages 53-66

  Fitzgerald, Kathleen A ^a   Guo, Jianfeng ^a   Tierney, Erica G ^b,d   Curtin, Caroline M ^b,d   Malhotra, Meenakshi ^a   Darcy, Raphael ^c   O'Brien, Fergal J ^b,d   O'Driscoll, Caitriona M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

3D bone cancer invitro model; Bone microenvironment; Collagen scaffolds; Gene therapy; Prostate cancer metastasis; SiRNA delivery

Indexed keywords

3D MODELING; ANTIGENS; BONE; CALCIUM COMPOUNDS; CELL CULTURE; CELL PROLIFERATION; COLLAGEN; GENE THERAPY; NANOPARTICLES; PATHOLOGY; SCAFFOLDS (BIOLOGY); THREE DIMENSIONAL DISPLAYS; UROLOGY;

BONE CANCER; COLLAGEN SCAFFOLDS; MICROENVIRONMENTS; PROSTATE CANCERS; SIRNA DELIVERY;

DISEASES;

COLLAGEN; COLLAGEN TYPE 1; DOCETAXEL; GELATINASE B; GLYCOSAMINOGLYCAN; HYDROXYAPATITE; INTEGRIN RECEPTOR; INTERSTITIAL COLLAGENASE; MOLECULAR SCAFFOLD; NANOHYDROXYAPATITE; PROSTATE SPECIFIC ANTIGEN; STROMELYSIN; UNCLASSIFIED DRUG; NANOCAPSULE; SMALL INTERFERING RNA;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INFILTRATION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA CONTENT; ENZYME RELEASE; GENE CONTROL; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; BATCH CELL CULTURE; BONE NEOPLASMS; CHEMISTRY; DEVICE FAILURE ANALYSIS; DEVICES; EQUIPMENT DESIGN; FEASIBILITY STUDY; GENE THERAPY; GENETICS; MALE; PATHOLOGY; PRECLINICAL STUDY; PROSTATE TUMOR; SECONDARY; THREE DIMENSIONAL PRINTING; TISSUE ENGINEERING; TISSUE SCAFFOLD; TUMOR CELL LINE;

BATCH CELL CULTURE TECHNIQUES; BONE NEOPLASMS; CELL LINE, TUMOR; COLLAGEN TYPE I; DRUG EVALUATION, PRECLINICAL; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FEASIBILITY STUDIES; GENETIC THERAPY; HUMANS; MALE; NANOCAPSULES; PRINTING, THREE-DIMENSIONAL; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84938149992     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.019     Document Type: Article

References (91)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2015 Jan-Feb, 65(1):5-29. PubMed PMID: 25559415.
2. Higano C.S. New treatment options for patients with metastatic castration-resistant prostate cancer. Cancer Treat. Rev. 2012 Aug, 38(5):340-345. PubMed PMID: 21944872.
3. Lee R.J., Saylor P.J., Smith M.R. Treatment and prevention of bone complications from prostate cancer. Bone 2011 Jan, 48(1):88-95. PubMed PMID: 20621630. Pubmed Central PMCID: 3010497.
4. Bi X., Sterling J.A., Merkel A.R., Perrien D.S., Nyman J.S., Mahadevan-Jansen A. Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice - a quantitative study using microCT and Raman spectroscopy. Bone 2013, 10, 56(2):454-460.
5. Harris V., Lloyd K., Forsey S., Rogers P., Roche M., Parker C. Apopulation-based study of prostate cancer chemotherapy. Clin. Oncol. 2011, 12, 23(10):706-708.
6. Petrylak D.P., Tangen C.M., Hussain M.H.A., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N.Engl. J. Med. 2004, 351(15):1513-1520. PubMed PMID: 15470214.
7. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N.Engl. J. Med. 2004, 351(15):1502-1512. PubMed PMID: 15470213.
8. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N.Engl. J. Med. 2011, 364(21):1995-2005. PubMed PMID: 21612468.
9. Scher H.I., Fizazi K., Saad F., Taplin M.-E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N.Engl. J. Med. 2012, 367(13):1187-1197. PubMed PMID: 22894553.
10. Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther. Adv. Med. Oncol. 2012 Nov, 4(6):329-340. PubMed PMID: 23118808. Pubmed Central PMCID: PMC3481557. (Epub 2012/11/03). eng.
11. Li Y., Chan S.C., Brand L.J., Hwang T.H., Silverstein K.A., Dehm S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013 Jan 15, 73(2):483-489. PubMed PMID: 23117885. Pubmed Central PMCID: PMC3549016. (Epub 2012/11/03). eng.
12. Fitzgerald K.A., Evans J.C., McCarthy J., Guo J., Prencipe M., Kearney M., et al. The role of transcription factors in prostate cancer and potential for future RNA interference therapy. Expert Opin. Ther. Targets 2014 Jun, 18(6):633-649. PubMed PMID: 24660778. (Epub 2014/03/26). eng.
13. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2006 Oct 15, 12(20 Pt 2):6243s-6249s. PubMed PMID: 17062708.
14. Lamb D.J., Zhang L. Challenges in prostate cancer research: animal models for nutritional studies of chemoprevention and disease progression. J.Nutr. 2005 Dec, 135(12 Suppl.):3009S-3015S. PubMed PMID: 16317162. (Epub 2005/12/01). eng.
15. Sieh S., Lubik A.A., Clements J.A., Nelson C.C., Hutmacher D.W. Interactions between human osteoblasts and prostate cancer cells in a novel 3D invitro model. Organogenesis 2010 Jul-Sep, 6(3):181-188. PubMed PMID: WOS:000290266200008. English.
16. Elliott N.T., Yuan F. Areview of three-dimensional invitro tissue models for drug discovery and transport studies. J.Pharm. Sci. 2011 Jan, 100(1):59-74. PubMed PMID: 20533556. (Epub 2010/06/10). eng.
17. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat. Mater. 2010 Feb, 9(2):90-93. PubMed PMID: WOS:000273810600002. English.
18. Xu X., Farach-Carson M.C., Jia X. Three-dimensional invitro tumor models for cancer research and drug evaluation. Biotechnol. Adv. 2014 Nov 15, 32(7):1256-1268. PubMed PMID: 25116894. Pubmed Central PMCID: 4171250.
19. Ellem S.J., De-Juan-Pardo E.M., Risbridger G.P. Invitro modeling of the prostate cancer microenvironment. Adv. Drug Deliv. Rev. 2014 May 9, 79-80. 214-221, PubMed PMID: 24816064.
20. Bayliss L., Mahoney D.J., Monk P. Normal bone physiology, remodelling and its hormonal regulation. Surg. Oxf. 2012, 2, 30(2):47-53.
21. Tierney C.M., Jaasma M.J., O'Brien F.J. Osteoblast activity on collagen-GAG scaffolds is affected by collagen and GAG concentrations. J.Biomed. Mater. Res. A 2009 Oct, 91A(1):92-101. PubMed PMID: WOS:000269627700011. English.
22. O'Brien F.J., Harley B.A., Yannas I.V., Gibson L. Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds. Biomaterials 2004 Mar, 25(6):1077-1086. PubMed PMID: 14615173. (Epub 2003/11/15). eng.
23. O'Brien F.J., Harley B.A., Yannas I.V., Gibson L.J. The effect of pore size on cell adhesion in collagen-GAG scaffolds. Biomaterials 2005 Feb, 26(4):433-441. PubMed PMID: 15275817. (Epub 2004/07/28). eng.
24. Murphy C.M., Haugh M.G., O'Brien F.J. The effect of mean pore size on cell attachment, proliferation and migration in collagen-glycosaminoglycan scaffolds for bone tissue engineering. Biomaterials 2010, 1, 31(3):461-466.
25. Cunniffe G.M., Dickson G.R., Partap S., Stanton K.T., O'Brien F.J. Development and characterisation of a collagen nano-hydroxyapatite composite scaffold for bone tissue engineering. J.Mater. Sci. Mater. Med. 2010 Aug, 21(8):2293-2298. PubMed PMID: 20091099. (Epub 2010/01/22). eng.
26. Shrivats A.R., McDermott M.C., Hollinger J.O. Bone tissue engineering: state of the union. Drug Discov. Today 2014 Jun, 19(6):781-786. PubMed PMID: 24768619.
27. Reichert J.C., Quent V.M.C., Burke L.J., Stansfield S.H., Clements J.A., Hutmacher D.W. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials 2010 Nov, 31(31):7928-7936. PubMed PMID: WOS:000282109100007. English.
28. Sieh S., Taubenberger A.V., Lehman M.L., Clements J.A., Nelson C.C., Hutmacher D.W. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D invitro culture reflect molecular changes during bone metastasis. Bone 2014 Jun, 63:121-131. PubMed PMID: 24530694. (Epub 2014/02/18). eng.
29. Cox R.F., Jenkinson A., Pohl K., O'Brien F.J., Morgan M.P. Osteomimicry of mammary adenocarcinoma cells invitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One 2012, 7(7):e41679. PubMed PMID: 22911843. Pubmed Central PMCID: 3404045.
30. Curtin C.M., Cunniffe G.M., Lyons F.G., Bessho K., Dickson G.R., Duffy G.P., et al. Innovative collagen nano-hydroxyapatite scaffolds offer a highly efficient non-viral gene delivery platform for stem cell-mediated bone formation. Adv. Mater. 2012 Feb 7, 24(6):749-754. PubMed PMID: 22213347.
31. 2+ compounds by precipitation in aqueous solution. Mater. Lett. 2011, 12, 65(23-24):3566-3569.
32. Hu J., Zhou Y., Huang L., Liu J., Lu H. Effect of nano-hydroxyapatite coating on the osteoinductivity of porous biphasic calcium phosphate ceramics. BMC Musculoskelet. Disord. 2014, 15:114. PubMed PMID: 24690170. Pubmed Central PMCID: 3994218.
33. Guo J., Ogier J.R., Desgranges S., Darcy R., O'Driscoll C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 2012 Nov, 33(31):7775-7784. PubMed PMID: 22828585. (Epub 2012/07/26). eng.
34. Guo J., Evans J.C., O'Driscoll C.M. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?. Trends Mol. Med. 2013 Apr, 19(4):250-261. PubMed PMID: 23499575.
35. O'Mahony A.M., Ogier J., Desgranges S., Cryan J.F., Darcy R., O'Driscoll C.M. Aclick chemistry route to 2-functionalised PEGylated and cationic beta-cyclodextrins: co-formulation opportunities for siRNA delivery. Org. Biomol. Chem. 2012 Jul 7, 10(25):4954-4960. PubMed PMID: 22614240.
36. Tierney E.G., McSorley K., Hastings C.L., Cryan S.A., O'Brien T., Murphy M.J., et al. High levels of ephrinB2 over-expression increases the osteogenic differentiation of human mesenchymal stem cells and promotes enhanced cell mediated mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix. J.Control. Release 2013 Feb 10, 165(3):173-182. PubMed PMID: WOS:000315680100002. English.
37. Cunniffe G.M., O'Brien F.J., Partap S., Levingstone T.J., Stanton K.T., Dickson G.R. The synthesis and characterization of nanophase hydroxyapatite using a novel dispersant-aided precipitation method. J.Biomed. Mater Res. A 2010, 95(5):1142-1149.
38. Haugh M.G., Jaasma M.J., O'Brien F.J. The effect of dehydrothermal treatment on the mechanical and structural properties of collagen-GAG scaffolds. J.Biomed. Mater. Res. A 2009 May, 89(2):363-369. PubMed PMID: 18431763. (Epub 2008/04/24). eng.
39. Sanchez-Sweatman O.H., Orr F.W., Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998, 18(5-6):297-305. PubMed PMID: 10729774. (Epub 2000/03/24). eng.
40. O'Mahony A.M., Ogier J., Darcy R., Cryan J.F., O'Driscoll C.M. Cationic and PEGylated amphiphilic cyclodextrins: co-formulation opportunities for neuronal sirna delivery. PLoS One 2013, 8(6):e66413.
41. O'Mahony A., Desgranges S., Ogier J., Quinlan A., Devocelle M., Darcy R., et al. Invitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery. Pharm. Res. 2013/04/01, 30(4):1086-1098. English.
42. Sung K.E., Su X., Berthier E., Pehlke C., Friedl A., Beebe D.J. Understanding the impact of 2D and 3D fibroblast cultures on invitro breast cancer models. PLoS One 2013, 8(10):e76373.
43. Fey S.J., Wrzesinski K. Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicol. Sci. 2012 Jun, 127(2):403-411. PubMed PMID: WOS:000304198400009. English.
44. Morgan M.P., Cooke M.M., Christopherson P.A., Westfall P.R., McCarthy G.M. Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines. Mol. Carcinog. 2001 Nov, 32(3):111-117. PubMed PMID: 11746823. (Epub 2001/12/18). eng.
45. Shi Z., Huang X., Cai Y., Tang R., Yang D. Size effect of hydroxyapatite nanoparticles on proliferation and apoptosis of osteoblast-like cells. Acta Biomater. 2009 Jan, 5(1):338-345. PubMed PMID: 18753024. (Epub 2008/08/30). eng.
46. Polini A., Pisignano D., Parodi M., Quarto R., Scaglione S. Osteoinduction of human mesenchymal stem cells by bioactive composite scaffolds without supplemental osteogenic growth factors. PLoS One 2011, 6(10):e26211.
47. Liberio M.S., Sadowski M.C., Soekmadji C., Davis R.A., Nelson C.C. Differential effects of tissue culture coating substrates on prostate cancer cell adherence, morphology and behavior. PLoS One 2014, 9(11):e112122. PubMed PMID: 25375165. Pubmed Central PMCID: PMC4223027. (Epub 2014/11/07). eng.
48. Sariisik E., Docheva D., Padula D., Popov C., Opfer J., Schieker M., et al. Probing the interaction forces of prostate cancer cells with collagen I and bone marrow derived stem cells on the single cell level. PLoS One 2013, 8(3):e57706. PubMed PMID: 23472100. Pubmed Central PMCID: 3589411.
49. Mujeeb A., Miller A.F., Saiani A., Gough J.E. Self-assembled octapeptide scaffolds for invitro chondrocyte culture. Acta Biomater. 2013, 1, 9(1):4609-4617.
50. Gill B.J., Gibbons D.L., Roudsari L.C., Saik J.E., Rizvi Z.H., Roybal J.D., et al. Asynthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res. 2012 Nov 15, 72(22):6013-6023. PubMed PMID: 22952217. Pubmed Central PMCID: PMC3632398. (Epub 2012/09/07). eng.
51. Matsusaki M., Yoshida H., Akashi M. The construction of 3D-engineered tissues composed of cells and extracellular matrices by hydrogel template approach. Biomaterials 2007 Jun, 28(17):2729-2737. PubMed PMID: 17336376. (Epub 2007/03/06). eng.
52. Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J.Urol. 2005 Feb, 173(2):342-359. PubMed PMID: 15643172. (Epub 2005/01/12). eng.
53. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J.Pathol. 1999, 189(3):300-308.
54. Bonfil R.D., Fridman R., Mobashery S., Cher M.L. Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?. Curr. Oncol. 2008 Aug, 15(4):188-192. PubMed PMID: 18769612. Pubmed Central PMCID: 2528310.
55. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 1993, 9:541-573. PubMed PMID: 8280471. (Epub 1993/01/01). eng.
56. McDonnell S., Fingleton B. Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors. Cytotechnology 1993, 12(1-3):367-384. PubMed PMID: 7764458. (Epub 1993/01/01). eng.
57. Wahl D.A., Czernuszka J.T. Collagen-hydroxyapatite composites for hard tissue repair. Eur. Cell Mater. 2006, 11:43-56. PubMed PMID: 16568401.
58. Hollas W., Hoosein N., Chung L.W., Mazar A., Henkin J., Kariko K., et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb. Haemost. 1992 Dec 7, 68(6):662-666. PubMed PMID: 1337629.
59. Aalinkeel R., Nair B.B., Reynolds J.L., Sykes D.E., Mahajan S.D., Chadha K.C., et al. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol. Invest. 2011, 40(5):447-464. PubMed PMID: 21391788. (Epub 2011/03/12). eng.
60. Singh S., Singh U.P., Grizzle W.E., Lillard J.W. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab. Invest. J. Tech. Methods Pathol. 2004 Dec, 84(12):1666-1676. PubMed PMID: 15467730.
61. Pulukuri S.M., Rao J.S. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int. J. Oncol. 2008 Apr, 32(4):757-765. PubMed PMID: 18360703. Pubmed Central PMCID: PMC2292413. (Epub 2008/03/25). eng.
62. Leto G., Badalamenti G., Arcara C., Crescimanno M., Flandina C., Tumminello F.M., et al. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Anticancer Res. 2006 Jan-Feb, 26(1A):23-26. PubMed PMID: 16475674.
63. Morgia G., Falsaperla M., Malaponte G., Madonia M., Indelicato M., Travali S., et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol. Res. 2005 Feb, 33(1):44-50. PubMed PMID: 15517230. (Epub 2004/11/02). eng.
64. Wang J., Levenson A.S., Satcher R.L. Identification of a unique set of genes altered during cell-cell contact in an invitro model of prostate cancer bone metastasis. Int. J. Mol. Med. 2006 May, 17(5):849-856. PubMed PMID: 16596270.
65. Millimaggi D., Festuccia C., Angelucci A., D'Ascenzo S., Rucci N., Flati S., et al. Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int. J. Oncol. 2006 Apr, 28(4):909-914. PubMed PMID: 16525640.
66. Sun T., McKay R., Lee G.M., Kantoff P. The role of miRNAs in prostate cancer. Eur. Urol. 2015 Jan 7, PubMed PMID: 25577717. 10.1016/j.eururo.2014.12.037.
67. Kim J., Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J.Cell. Biochem. 2004 Oct 1, 93(2):233-241. PubMed PMID: 15368351.
68. Freedland S.J., Hotaling J.M., Fitzsimons N.J., Presti J.C., Kane C.J., Terris M.K., et al. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes-results from the SEARCH database. Eur. Urol. 2008 Apr, 53(4):758-764. (discussion 65-6). PubMed PMID: 17868976.
69. Chow P.-M., Chiang I.N., Cheng J.C.-H., Chiang B.-J., Pu Y.-S., Huang C.-Y. Pretreatment prostate specific antigen (PSA) and 2-year PSA dynamics: early predictors of prostate cancer prognosis with external radiation therapy. Urol. Sci. 2013, 12, 24(4):120-123.
70. Takahashi T., Hoshi S., Satoh M., Kaneda T., Suzuki K.I., Nakagawara K.I., et al. The study of PSA gene expression on urogenital cell lines. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 1999 Oct, 6(10):526-531. PubMed PMID: 10533904.
71. Tai S., Sun Y., Squires J.M., Zhang H., Oh W.K., Liang C.Z., et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011 Nov, 71(15):1668-1679. PubMed PMID: 21432867. Pubmed Central PMCID: PMC3426349. (Epub 2011/03/25). eng.
72. Zhu Y.S., Cai L.Q., You X., Cordero J.J., Huang Y., Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J.Androl. 2003 Sep-Oct, 24(5):681-687. PubMed PMID: 12954658. (Epub 2003/09/05). eng.
73. Edwards I.J. Proteoglycans in prostate cancer. Nat. Rev. Urol. 2012 Apr, 9(4):196-206. PubMed PMID: 22349653.
74. Talukdar S., Kundu S.C. Anon-mulberry silk fibroin protein based 3D invitro tumor model for evaluation of anticancer drug activity. Adv. Funct. Mater. 2012 Nov 21, 22(22):4778-4788. PubMed PMID: WOS:000310966500015. English.
75. Kim Y.J., Bae H.I., Kwon O.K., Choi M.S. Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test. Int. J. Biol. Macromol. 2009 Jul 1, 45(1):65-71. PubMed PMID: 19375451.
76. David L., Dulong V., Le Cerf D., Cazin L., Lamacz M., Vannier J.P. Hyaluronan hydrogel: an appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomater. 2008 Mar, 4(2):256-263. PubMed PMID: 17936097.
77. Xu X., Sabanayagam C.R., Harrington D.A., Farach-Carson M.C., Jia X. Ahydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics. Biomaterials 2014 Mar, 35(10):3319-3330. PubMed PMID: 24447463. Pubmed Central PMCID: 3929180.
78. Chambers K.F., Mosaad E.M., Russell P.J., Clements J.A., Doran M.R. 3D cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. PLoS One 2014, 9(11):e111029. PubMed PMID: 25380249. Pubmed Central PMCID: 4224379.
79. Holmes C., Daoud J., Bagnaninchi P.O., Tabrizian M. Polyelectrolyte multilayer coating of 3D scaffolds enhances tissue growth and gene delivery: non-invasive and label-free assessment. Adv. Healthc. Mater. 2014 Apr, 3(4):572-580. PubMed PMID: 24030932. (Epub 2013/09/14). eng.
80. Capito R.M., Spector M. Collagen scaffolds for nonviral IGF-1 gene delivery in articular cartilage tissue engineering. Gene Ther. 2007/02/22, 14(9):721-732. online.
81. Aviles M.O., Lin C.H., Zelivyanskaya M., Graham J.G., Boehler R.M., Messersmith P.B., et al. The contribution of plasmid design and release to invivo gene expression following delivery from cationic polymer modified scaffolds. Biomaterials 2010 Feb, 31(6):1140-1147. PubMed PMID: 19892398. Pubmed Central PMCID: PMC2821673. (Epub 2009/11/07). eng.
82. Lei Y., Huang S., Sharif-Kashani P., Chen Y., Kavehpour P., Segura T. Incorporation of active DNA/cationic polymer polyplexes into hydrogel scaffolds. Biomaterials 2010 Dec, 31(34):9106-9116. PubMed PMID: 20822811. Pubmed Central PMCID: PMC3017740. (Epub 2010/09/09). eng.
83. Li B., Li F., Ma L., Yang J., Wang C., Wang D., et al. Poly(lactide-co-glycolide)/fibrin gel construct as a 3D model to evaluate gene therapy of cartilage invivo. Mol. Pharm. 2014/07/07, 11(7):2062-2070.
84. McCarthy J., O'Neill M.J., Bourre L., Walsh D., Quinlan A., Hurley G., et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. J.Control. Release Off. J. Control. Release Soc. 2013 May 28, 168(1):28-34. PubMed PMID: 23500058. (Epub 2013/03/19). eng.
85. Godinho B.M., Ogier J.R., Darcy R., O'Driscoll C.M., Cryan J.F. Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol. Pharm. 2013 Feb 4, 10(2):640-649. PubMed PMID: 23116281. (Epub 2012/11/03). eng.
86. O'Mahony A.M., Godinho B.M., Ogier J., Devocelle M., Darcy R., Cryan J.F., et al. Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery. ACS Chem. Neurosci. 2012 Oct 17, 3(10):744-752. PubMed PMID: 23077718. Pubmed Central PMCID: PMC3474283. (Epub 2012/10/19). eng.
87. Anderson E.M., Miller P., Ilsley D., Marshall W., Khvorova A., Stein C.A., et al. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther. 2006 Apr, 13(4):406-414. PubMed PMID: 16195754.
88. Cao C., Subhawong T., Albert J.M., Kim K.W., Geng L., Sekhar K.R., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006 Oct 15, 66(20):10040-10047. PubMed PMID: 17047067.
89. Kojima K., Ohhashi R., Fujita Y., Hamada N., Akao Y., Nozawa Y., et al. Arole for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 2008 Aug 29, 373(3):423-428. PubMed PMID: 18573234.
90. Thulin M.H., Jennbacken K., Damber J.E., Welen K. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for invitro and invivo studies. Clin. Exp. Metastas. 2014 Mar, 31(3):269-283. PubMed PMID: WOS:000330948200001. English.
91. Wang R., Xu J., Juliette L., Castilleja A., Love J., Sung S.Y., et al. Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. Semin. Cancer Biol. 2005 Oct, 15(5):353-364. PubMed PMID: 15982899.